



Pharmaceuticals

January 15, 2008

Dear Healthcare Professional,

This letter is to advise you of an immediate back-order situation with one of our antineoplastic agent, ZANOSAR* (IV streptozocin 1G sterile powder) indicated for the treatment of metastatic islet cell carcinoma of the pancreas.

Understanding the medical necessity of this product for some patients, our Medical Information team has been diligently rationing the product on a case by case basis since October 2007 in an attempt to secure the availability of the product for all Canadians in great need of this medication. Unfortunately, due to additional delays in receiving further supplies, a back-order situation cannot be avoided.

This situation is not limited to Canada but also affects other countries worldwide and is caused by a global shortage of the active primary ingredient from our vendor. Kindly note that Pfizer Inc. is doing everything within its power to secure a prolonged and continuous supply of ZANOSAR. However, it is impossible to speculate as to when this medication will once again be available on the Canadian market.

As there is no equivalent drug in Canada, alternative options will therefore need to be considered for each patient. Pfizer Canada Inc. does not have specific recommendations in this regard. Which treatment to pursue will need to be chosen by the physician/oncologist based on his/her clinical judgment and the patient's medical condition and history.

We understand the critical importance of the situation and sincerely apologize for any inconvenience this shortage may cause you and your patients. Rest assured Pfizer Canada Inc. will keep you informed on the ZANOSAR supply situation as it evolves.

Should you have any question on ZANOSAR, please do not hesitate to contact our Medical Information service at 1 800 463-6001 options #1, 2. This communication can also be found on our website at www.pfizer.ca.

Sincerely,

A handwritten signature in black ink that reads "Caroline Croteau".

Caroline Croteau, B. Pharm., M.Sc.
Director, Medical Information Services

A handwritten signature in black ink that reads "Dr. Pierre Franquet".

Dr. Pierre Franquet
Manager, Portfolio Planning
Pain, CNS, Inflammation, Urology, Migraine,
Respiratory, Non-Promoted Products